Impacts of a Brazilian pharmaceutical program on the health of chronic patients
ABSTRACT OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
2019-01-01
|
Series: | Revista de Saúde Pública |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102019000100217&lng=en&tlng=en |
id |
doaj-44120ed5d86f460c8abd1cf3f276a1ee |
---|---|
record_format |
Article |
spelling |
doaj-44120ed5d86f460c8abd1cf3f276a1ee2020-11-24T21:14:20ZengUniversidade de São PauloRevista de Saúde Pública1518-87872019-01-0153010.11606/s1518-8787.2019053000733S0034-89102019000100217Impacts of a Brazilian pharmaceutical program on the health of chronic patientsAléssio Tony Cavalcanti de AlmeidaEdvaldo Batista de SáFabiola Sulpino VieiraRodrigo Pucci de Sá e BenevidesABSTRACT OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical model of fixed-effect difference in differences was used, considering: the divisions Rede Própria (RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure time of the municipality to the program; intramunicipal density, measured by the number of accredited establishments; and the coverage spillover effect into patients from nonparticipating municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM – Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital Information System); ii) other health data managed by the Departamento de Informática do SUS (DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de Informações Sociais (RAIS – Annual List of Social Information). RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, respectively. The observed impacts were induced by the partnership network, highlighting the density of establishments per 100,000 inhabitants and, above all, the exposure time of the municipality to the program as relevant to the effect. Evidence of a spillover effect and of the maintenance of impacts on different age groups, especially older people, were also observed. CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102019000100217&lng=en&tlng=enChronic Disease, drug therapyPharmaceutical ServicesProgram EvaluationNational Policy of Pharmaceutical Assistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aléssio Tony Cavalcanti de Almeida Edvaldo Batista de Sá Fabiola Sulpino Vieira Rodrigo Pucci de Sá e Benevides |
spellingShingle |
Aléssio Tony Cavalcanti de Almeida Edvaldo Batista de Sá Fabiola Sulpino Vieira Rodrigo Pucci de Sá e Benevides Impacts of a Brazilian pharmaceutical program on the health of chronic patients Revista de Saúde Pública Chronic Disease, drug therapy Pharmaceutical Services Program Evaluation National Policy of Pharmaceutical Assistance |
author_facet |
Aléssio Tony Cavalcanti de Almeida Edvaldo Batista de Sá Fabiola Sulpino Vieira Rodrigo Pucci de Sá e Benevides |
author_sort |
Aléssio Tony Cavalcanti de Almeida |
title |
Impacts of a Brazilian pharmaceutical program on the health of chronic patients |
title_short |
Impacts of a Brazilian pharmaceutical program on the health of chronic patients |
title_full |
Impacts of a Brazilian pharmaceutical program on the health of chronic patients |
title_fullStr |
Impacts of a Brazilian pharmaceutical program on the health of chronic patients |
title_full_unstemmed |
Impacts of a Brazilian pharmaceutical program on the health of chronic patients |
title_sort |
impacts of a brazilian pharmaceutical program on the health of chronic patients |
publisher |
Universidade de São Paulo |
series |
Revista de Saúde Pública |
issn |
1518-8787 |
publishDate |
2019-01-01 |
description |
ABSTRACT OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical model of fixed-effect difference in differences was used, considering: the divisions Rede Própria (RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure time of the municipality to the program; intramunicipal density, measured by the number of accredited establishments; and the coverage spillover effect into patients from nonparticipating municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM – Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital Information System); ii) other health data managed by the Departamento de Informática do SUS (DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de Informações Sociais (RAIS – Annual List of Social Information). RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, respectively. The observed impacts were induced by the partnership network, highlighting the density of establishments per 100,000 inhabitants and, above all, the exposure time of the municipality to the program as relevant to the effect. Evidence of a spillover effect and of the maintenance of impacts on different age groups, especially older people, were also observed. CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments. |
topic |
Chronic Disease, drug therapy Pharmaceutical Services Program Evaluation National Policy of Pharmaceutical Assistance |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102019000100217&lng=en&tlng=en |
work_keys_str_mv |
AT alessiotonycavalcantidealmeida impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients AT edvaldobatistadesa impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients AT fabiolasulpinovieira impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients AT rodrigopuccidesaebenevides impactsofabrazilianpharmaceuticalprogramonthehealthofchronicpatients |
_version_ |
1716747674579894272 |